About your role
As a PhD candidate in this project you will:
- design and synthesize biologically active compounds targeting the protein of interest;
- radiolabel selected compounds with tritium and PET radionuclides (fluorine-18 and/or carbon-11);
- perform autoradiography, binding studies, and functional in vitro assays;
- work closely with our collaborators;
- present your findings at scientific meetings, symposia, and international conferences;
- contribute to teaching activities and supervision of BSc and MSc students.
About youWe are looking for an ambitious and motivated candidate who meets the following requirements:
- a MSc degree in medicinal chemistry or a closely related discipline;
- demonstrated experience in synthetic organic chemistry;
- a strong interest in drug/tracer development;
- the ability to work collaboratively in an interdisciplinary research environment;
- excellent communication skills in English, both written and spoken.
Our offer- The intended start date for the project is September 1, 2026.
- You will be employed by Amsterdam UMC Research BV.
- A contract for 12 months, with the intention to extend for a total of four years. The Guideline PhD contract applies to this vacancy.
- Classification in salary scale OIO: € 3.108 to € 3.939 gross for full-time employment (depending on experience). In addition to a good basic salary, we offer 8.3% end-of-year bonus. Calculate your net salary here. As of 1 July 2026, the salary will be increased by 3.5% in accordance with the collective labor agreement (CAO UMC).
- Holiday hours: 194.4 per year for full time and a possibility to save additional hours.
- 100% reimbursement for public transport travel costs. If you travel by foot, bicycle, or car, a mileage allowance of €0.21 per km applies (up to a maximum of 40 km one way by car).
- Do you prefer walking or cycling? Take advantage of our good bike scheme.
- Pension accrual with BeFrank, a modern, comprehensible and fairly priced pension.
- Watch this video with more information about joining Amsterdam UMC Research BV.
